^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-1088

    i
    Other names: MK-1088
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> May 2025 | Trial primary completion date: Nov 2025 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • MK-1088
    over2years
    A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy/ single agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (clinicaltrialsregister.eu)
    P1/2, N=80, Ongoing, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    New P1/2 trial • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-1088